Aulos Biosciences
Clinical-stage biotechnology company developing a new class of immunotherapies that selectively activate immune cells to fight cancer while avoiding suppressive regulatory pathways.
Location
Waltham, Massachusetts, USA
Founded
2019
Investors
1
Categories
biotech, immunotherapy, oncology, il-2, therapeutics
Notes
Aulos Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies for cancer treatment. The company's lead program, AU-007 (Imnekibart), is an anti-IL-2 antibody designed to redirect the body's endogenous IL-2 to activate and expand cancer-fighting immune cells while avoiding regulatory T cells that can suppress anti-tumor immunity.
The company is advancing AU-007 in clinical trials for multiple cancer indications including melanoma and non-small cell lung cancer (NSCLC).
Team
- Robert Kastelein, M.D., Ph.D. - Co-Founder and CEO
- Peter van de Vliet, M.D. - Chief Medical Officer
- David Chang, M.D., Ph.D. - Board Member
Additional Research Findings
- Lead program AU-007 (Imnekibart) is an anti-IL-2 antibody
- Focus on redirecting endogenous IL-2 to cancer-fighting immune cells
- Clinical trials in melanoma and NSCLC
- Novel approach to overcome limitations of traditional IL-2 therapy
- Backed by leading biotech investors
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Apple Tree Partners | New York, USA | biotech-focused | series-aseries-b+2 | 23 |